Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00362375 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Healthy Love Workshop, an HIV Prevention Intervention for African American Women
A Phase 1 study of HIV Infections and Sexually Transmitted Infections, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- Phase 1
- Development phase
- 313
- Enrollment target
- 1
- Study location
NCT00362375: Completed Phase 1 study of HIV Infections and Sexually Transmitted Infections, sponsored by Centers for Disease Control and Prevention.
NCT00362375 is a Phase 1 study of HIV Infections and Sexually Transmitted Infections that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 313 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00362375, a Phase 1 study of HIV Infections and Sexually Transmitted Infections, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 313 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this program evaluation is to determine whether the Health Love Workshop, a group-level HIV behavioral intervention, reduces HIV-related sex risk behaviors and increases HIV protective behaviors of African American women and women of African descent. The intent of this program is to support an evaluation of the efficacy of the intervention and to provide feedback to the implementing organization to increase intervention effectiveness.
Primary Outcome
Percentage of women who used condoms during vaginal intercourse with any male partner during the past 3 months
Conditions Studied
Interventions
- BEHAVIORAL Healthy Love Workshop
- BEHAVIORAL HIV/AIDS 101 Workshop
Study Locations (1)
Georgia
- SisterLove, Inc. - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 313 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
What the finished NCT00362375 record still lists
NCT00362375 is an interventional study that assigns participants to a tested intervention. The registered 313 participants enrollment target is mid-sized for trials with a published cap, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (30% lower).
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Healthy Love Workshop is the first listed.
NCT00362375 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT00362375 about?
NCT00362375 is a clinical study titled "Evaluation of the Healthy Love Workshop, an HIV Prevention Intervention for African American Women". The purpose of this program evaluation is to determine whether the Health Love Workshop, a group-level HIV behavioral intervention, reduces HIV-related sex risk behaviors and increases HIV protective behaviors of African American women and women of African descent. The intent of this program is to s...
What is the current status of trial NCT00362375?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 313 participants. The study started on 2006-05. Estimated completion is 2008-04.
What conditions does trial NCT00362375 study?
This clinical trial studies the following conditions: HIV Infections, Sexually Transmitted Infections.
What interventions are being tested in trial NCT00362375?
The interventions under investigation include: Healthy Love Workshop (BEHAVIORAL), HIV/AIDS 101 Workshop (BEHAVIORAL).
Who is sponsoring clinical trial NCT00362375?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00362375 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00362375's enrollment target sits among peer trials
313 114th of 542 higher than 429 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00595491 · 313 participants · Phase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
- NCT03866382 · 314 participants · Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- NCT04500756 · 314 participants · Phase 2
Limiting AAA With Metformin (LIMIT) Trial
- NCT06167746 · 314 participants · Phase 3
iCare4Me Transitions
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia